The ecology of cancer from an evolutionary game theory perspective

Interface Focus

Volumn 4, Issue 4, 2014, Pages

  Pacheco, Jorge M ^a,b,c   Santos, Francisco C ^c,d   Dingli, David ^e  

^a Departamento de Matemática e Aplicações   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c Universidade de Lisboa   (Portugal)

^d INSTITUTO SUPERIOR TÉCNICO   (Portugal)

^e MAYO CLINIC   (United States)

Author keywords

Cancer ecology; Cell population dynamics; Evolutionary game theory; Fitness driven dynamics; Frequency dependent selection; Somatic evolution of cancer

Indexed keywords

EID: 84903179349     PISSN: 20428898     EISSN: 20428901     Source Type: Journal    
DOI: 10.1098/rsfs.2014.0019     Document Type: Article

References (58)

1. Cairns J. 1975 Mutation selection and the natural history of cancer. Nature 255, 197-200. (doi:10.1038/255197a0)
2. Hanahan D, Weinberg RA. 2011 Hallmarks of cancer: the next generation. Cell 144, 646-674. (doi:10.1016/j.cell.2011.02.013)
3. Vogelstein B, Kinzler KW. 2004 Cancer genes and the pathways they control. Nat. Med. 10, 789-799. (doi:10.1038/nm1087)
4. Kunkel TA, Bebenek K. 2000 DNA replication fidelity 1. Annu. Rev. Biochem. 69, 497-529. (doi:10.1146/annurev.biochem.69.1.497)
5. Araten DJ, Golde DW, Zhang RH, Thaler HT, Gargiulo L, Notaro R, Luzzatto L. 2005 A quantitative measurement of the human somatic mutation rate. Cancer Res. 65, 8111-8117. (doi:10.1158/0008- 5472.CAN-04-1198)
6. Peruzzi B, Araten DJ, Notaro R, Luzzatto L. 2010 The use of PIG-A as a sentinel gene for the study of the somatic mutation rate and of mutagenic agents in vivo. Mutat. Res. Rev. Mutat. Res. 705, 3-10. (doi:10.1016/j.mrrev.2009.12.004)
7. Traulsen A, Pacheco JM, Luzzatto L, Dingli D. 2010 Somatic mutations and the hierarchy of hematopoiesis. Bioessays 32, 1003-1008. (doi:10. 1002/bies.201000025)
8. Kandoth C et al. 2013 Mutational landscape and significance across 12 major cancer types. Nature 502, 333-339. (doi:10.1038/nature12634)
9. Junttila MR, de Sauvage FJ. 2013 Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501, 346-354. (doi:10.1038/nature12626)
10. Hofbauer J, Sigmund K. 1998 Evolutionary games and population dynamics. Cambridge, UK: Cambridge University Press.
11. Nowak MA. 2006 Evolutionary dynamics. Cambridge, MA: Belknap/Harvard.
12. Traulsen A, Pacheco JM, Imhof LA. 2006 Stochasticity and evolutionary stability. Phys. Rev. E Stat. Nonlin. Soft Matter. Phys. 74, 021905. (doi:10.1103/PhysRevE.74.021905)
13. Lopes JV, Pacheco JM, Dingli D. 2007 Acquired hematopoietic stem-cell disorders and mammalian size. Blood 110, 4120-4122. (doi:10.1182/blood- 2007-05-089805)
14. Dingli D, Traulsen A, Pacheco JM. 2007 Compartmental architecture and dynamics of hematopoiesis. PLoS ONE 2, e345. (doi:10.1371/ journal.pone.0000345)
15. Gordon M, Blackett N. 1994 Routes to repopulation: a unification of the stochastic model and separation of stem-cell subpopulations. Leukemia 8, 1068-1072; discussion 1072-3.
16. Abkowitz JL, Catlin SN, Guttorp P. 1996 Evidence that hematopoiesis may be a stochastic process in vivo. Nat. Med. 2, 190-197. (doi:10.1038/nm0296-190)
17. Dingli D, Traulsen A, Michor F. 2007 (A) symmetric stem cell replication and cancer. PLoS Comput. Biol. 3, e53. (doi:10.1371/journal.pcbi.0030053)
18. Shahriyari L, Komarova NL. 2013 Symmetric vs. asymmetric stem cell divisions: an adaptation against cancer? PLoS ONE 8, e76195. (doi:10.1371/ journal.pone.0076195)
19. Wodarz D, Komarova NL. 2005 Computational biology of cancer: lecture notes and mathematical modeling. Singapore: World Scientific.
20. Lenaerts T, Pacheco JM, Traulsen A, Dingli D. 2010 Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells. Haematologica 95, 900-907. (doi:10.3324/ haematol.2009.015271)
21. Lenaerts T, Castagnetti F, Traulsen A, Pacheco JM, Rosti G, Dingli D. 2011 Explaining the in vitro and in vivo differences in leukemia therapy. Cell cycle 10, 1540-1544. (doi:10.4161/cc.10.10.15518)
22. Traulsen A, Pacheco JM, Dingli D. 2010 Reproductive fitness advantage of BCR-ABL expressing leukemia cells. Cancer Lett. 294, 43-48. (doi:10.1016/j.canlet.2010.01.020)
23. Dingli D, Traulsen A, Pacheco JM. 2008 Chronic myeloid leukemia: origin, development, response to therapy, and relapse. Clin. Leuk. 2, 133-139. (doi:10.3816/CLK.2008.n.017)
24. Santos FC, Pacheco JM. 2011 Risk of collective failure provides an escape from the tragedy of the commons. Proc. Natl Acad. Sci. USA 108, 10 421- 10 425. (doi:10.1073/pnas.1015648108)
25. Vasconcelos VV, Santos FC, Pacheco JM. 2013 A bottom-up institutional approach to cooperative governance of risky commons. Nat. Clim. Change 3, 797-801. (doi:10.1038/nclimate1927)
26. Kyle RA, Rajkumar SV. 2004 Multiple myeloma. N. Engl. J. Med. 351, 1860-1873. (doi:10.1056/ NEJMra041875)
27. Berenson JR. 2001 Bone disease in myeloma. Curr. Treat. Options Oncol. 2, 271-283. (doi:10.1007/ s11864-001-0041-5)
28. Harper KD, Weber TJ. 1998 Secondary osteoporosis. Diagnostic considerations. Endocrinol. Metab. Clin. North Am. 27, 325-348. (doi:10.1016/S0889- 8529(05)70008-6)
29. Bergsagel PL, Kuehl WM. 2005 Molecular pathogenesis and a consequent classification of multiple myeloma. J. Clin. Oncol. 23, 6333-6338. (doi:10.1200/JCO.2005.05.021)
30. Kuehl WM, Bergsagel PL. 2002 Multiple myeloma: evolving genetic events and host interactions. Nat. Rev. Cancer 2, 175-187. (doi:10.1038/nrc746)
31. Roodman GD. 2004 Pathogenesis of myeloma bone disease. Blood Cells Mol. Dis. 32, 290-292. (doi:10. 1016/j.bcmd.2004.01.001)
32. Terpos E, Sezer O, Croucher P, Dimopoulos MA. 2007 Myeloma bone disease and proteasome inhibition therapies. Blood 110, 1098-1104. (doi:10.1182/ blood-2007-03067710)
33. Raje N, Roodman GD. 2011 Advances in the biology and treatment of bone disease in multiple myeloma. Clin. Cancer Res. 17, 1278-1286. (doi:10.1158/1078-0432.CCR-10-1804)
34. Dinarello CA. 2009 Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 27, 519-550. (doi:10.1146/annurev. immunol.021908.132612)
35. Croucher PI et al. 2001 Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98, 3534-3540. (doi:10.1182/ blood.V98.13.3534)
36. Choi SJ, Cruz JC, Craig F, Chung H, Devlin RD, Roodman GD, Alsina M. 2000 Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 96, 671-675.
37. Roux S, Mariette X. 2004 The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kB) and RANK ligand expression. Leuk. Lymphoma 45, 1111- 1118. (doi:10.1080/10428194310001593193)
38. Qiang YW, Barlogie B, Rudikoff S, Shaughnessy Jr JD. 2008 Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. Bone 42, 669-680. (doi:10.1016/j.bone.2007.12.006)
39. Qiang YW, Chen Y, Stephens O, Brown N, Chen B, Epstein J, Barlogie B, Shaughnessy Jr JD. 2008 Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 112, 196-207. (doi:10.1182/blood-2008-01-132134)
40. Qiang YW, Shaughnessy Jr JD, Yaccoby S. 2008 Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood 112, 374-382. (doi:10.1182/blood-2007- 10-120253)
41. Epstein J, Yaccoby S. 2003 Consequences of interactions between the bone marrow stroma and myeloma. Hematol. J. 4, 310-314. (doi:10.1038/sj.thj.6200313)
42. Jelinek DF. 1999 Mechanisms of myeloma cell growth control. Hematol. Oncol. Clin. North Am. 13, 1145-1157. (doi:10.1016/S0889-8588(05)70117-9)
43. Abe M et al. 2004 Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 104, 2484-2491. (doi:10.1182/ blood-2003-11-3839)
44. Maynard-Smith J. 1982 Evolution and the theory of games. Cambridge, UK: Cambridge University Press.
45. Roodman GD. 2002 Role of the bone marrow microenvironment in multiple myeloma. J. Bone Miner. Res. 17, 1921-1925. (doi:10.1359/jbmr.2002.17.11.1921)
46. Bataille R, Harousseau JL. 1997 Multiple myeloma. N. Engl. J. Med. 336, 1657-1664. (doi:10.1056/NEJM199706053362307)
47. Dingli D, Chalub FACC, Santos FC, Van Segbroeck S, Pacheco JM. 2009 Cancer phenotype as the outcome of an evolutionary game between normal and malignant cells. Br. J. Cancer 101, 1130-1136. (doi:10.1038/sj.bjc.6605288)
48. Terpos E, Politou M, Rahemtulla A. 2003 New insights into the pathophysiology and management of bone disease in multiple myeloma. Br. J. Haematol. 123, 758-769. (doi:10.1046/j.1365-2141.2003.04712.x)
49. Hashimoto T, Abe M, Oshima T, Shibata H, Ozaki S, Inoue D, Matsumoto T. 2004 Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma. Br. J. Haematol. 125, 38-41. (doi:10.1111/j.1365- 2141.2004.04864.x)
50. Dinarello CA. 2009 Targeting the pathogenic role of interleukin 1b in the progression of smoldering/ indolent myeloma to active disease. Mayo Clin. Proc. 84, 105-107. (doi:10.4065/84.2.105)
51. Lust JA et al. 2009 Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1b-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin. Proc. 84, 114-122. (doi:10.4065/84.2.114)
52. Choi SJ, Oba Y, Gazitt Y, Alsina M, Cruz J, Anderson J, Roodman GD. 2001 Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J. Clin. Invest. 108, 1833-1841. (doi:10.1172/JCI200113116)
53. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy Jr JD. 2007 Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 109, 2106-2111. (doi:10.1182/blood-2006-09-047712)
54. Ng AC et al. 2011 Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1a levels in patients with MGUS. Blood 118, 6529-6534. (doi:10.1182/blood-2011-04-351437)
55. Farr JN, Zhang W, Kumar SK, Jacques RM, Ng AC, McCready LK, Rajkumar SV, Drake MT. 2014 Altered cortical microarchitecture in patients with monoclonal gammopathy of undetermined significance. Blood 123, 647-649. (doi:10.1182/blood-2013-05-505776)
56. Morgan GJ et al. 2013 Long-term follow-up of MRC Myeloma IX Trial: survival outcomes with bisphosphonate and thalidomide treatment. Clin. Cancer Res. 19, 6030-6038. (doi:10.1158/1078-0432.CCR-12-3211)
57. Chapman MA et al. 2011 Initial genome sequencing and analysis of multiple myeloma. Nature 471, 467-472. (doi:10.1038/nature09837)
58. Kumar SK et al. 2012 Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood 119, 4860-4867. (doi:10.1182/blood-2012-01-407791)